Paul L. Berns's most recent trade in Neumora Therapeutics Inc. was a trade of 2,000,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 May 2025 | 2,000,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 2,000,000 | 2,000,000 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 955,864 | 955,864 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 May 2025 | 955,864 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 May 2025 | 497,049 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 497,049 | 497,049 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 May 2025 | 342,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2025 | 342,500 | 342,500 | - | - | Stock Option (Right to Buy) | |
| Metsera Inc. | Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2025 | 24,188 | 24,188 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 1.69 per share. | 18 Feb 2025 | 13,871 | 7,405,004 | - | 1.7 | 23,468 | Common Stock |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 2,000,000 | 2,000,000 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 955,864 | 955,864 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 955,864 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 497,049 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 497,049 | 497,049 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 342,500 | 342,500 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Paul L. Berns | Director, See Remarks | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 342,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Metsera Inc. | Paul L. Berns | Director | 03 Feb 2025 | 15,000,000 | 0 | - | - | Series A Convertible Preferred Stock | ||
| Metsera Inc. | Paul L. Berns | Director | 03 Feb 2025 | 7,523,682 | 7,523,682 | - | - | Common Stock | ||
| Metsera Inc. | Paul L. Berns | Director | 03 Feb 2025 | 2,678,571 | 0 | - | - | Series B Convertible Preferred Stock | ||
| Metsera Inc. | Paul L. Berns | Director | Purchase of securities on an exchange or from another person at price $ 18.00 per share. | 03 Feb 2025 | 789,998 | 8,313,680 | - | 18 | 14,219,964 | Common Stock |
| Neumora Therapeutics Inc. | Berns Paul L. | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Dec 2024 | 133,097 | 7,685,069 | - | 0 | Common Stock | |
| Neumora Therapeutics Inc. | Berns L. Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Dec 2024 | 133,097 | 7,551,972 | - | 0 | Common Stock | |
| Neumora Therapeutics Inc. | L. Berns Paul | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Dec 2024 | 133,097 | 7,418,875 | - | 0 | Common Stock | |
| Unity Biotechnology Inc | Paul L. Berns | Director | 21 Jun 2024 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | ||
| Neumora Therapeutics Inc. | Paul Berns L. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 342,500 | 342,500 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | L. Berns Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 171,250 | 7,818,166 | - | 0 | Common Stock | |
| Unity Biotechnology Inc | Paul L. Berns | Director | 23 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | ||
| EQRx Inc | Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2023 | 453 | 86,344 | - | - | Earn-out Shares | |
| EQRx Inc | Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 101,010 | 101,010 | - | - | Stock Option (Right to Buy) | |
| Unity Biotechnology Inc | Paul L. Berns | Director | 24 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | ||
| EQRx Inc | Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 627,000 | 627,000 | - | - | Common Stock | |
| EQRx Inc | Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 85,891 | 85,891 | - | - | Earn-out Shares | |
| Jazz Pharmaceuticals plc | Paul L. Berns | Director | Sale of securities on an exchange or to another person at price $ 154.00 per share. | 05 Aug 2021 | 1,450 | 8,290 (0%) | 0% | 154 | 223,300 | Ordinary Shares |
| Unity Biotechnology Inc | Paul L. Berns | Director | 24 Jun 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | ||
| Jazz Pharmaceuticals plc | Paul L. Berns | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 4,691 | 14,431 (0%) | 0% | - | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Paul L. Berns | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2020 | 4,691 | 0 | - | - | Phantom Stock | |
| Jazz Pharmaceuticals plc | Paul L. Berns | Director | Sale of securities on an exchange or to another person at price $ 150.90 per share. | 02 Nov 2020 | 3,825 | 9,740 (0%) | 0% | 150.9 | 577,186 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Paul L. Berns | Director | Sale of securities on an exchange or to another person at price $ 147.44 per share. | 02 Nov 2020 | 466 | 13,965 (0%) | 0% | 147.4 | 68,707 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Paul L. Berns | Director | Sale of securities on an exchange or to another person at price $ 149.28 per share. | 02 Nov 2020 | 400 | 13,565 (0%) | 0% | 149.3 | 59,711 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 6,765 | 6,765 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jazz Pharmaceuticals plc | Paul L. Berns | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 2,705 | 10,671 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Paul L. Berns | Director | Sale of securities on an exchange or to another person at price $ 125.87 per share. | 06 Aug 2020 | 931 | 9,740 (0%) | 0% | 125.9 | 117,185 | Ordinary Shares |